查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2149284

腫瘤生物相似藥市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Oncology Biosimilars Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

腫瘤生物相似藥市場成長要素

2025年全球腫瘤生物相似藥市場規模為98億美元，預計將從2026年的107.4億美元成長至2034年的322.5億美元，預測期內複合年成長率（CAGR）為14.73%。亞太地區引領市場，預計2025年將佔32.95%的市場佔有率（市場規模達32.3億美元），這主要得益於癌症發病率的上升、對生物製藥療法的需求不斷成長、國內生物製藥生產規模的擴大以及法規結構的完善。生物相似藥的日益普及正在幫助醫療系統擴大癌症治療的覆蓋範圍，同時控制治療成本。

在腫瘤領域，生物相似藥正日益被廣泛接受，成為參考生物製藥（包括單株抗體和免疫腫瘤療法）的經濟有效的替代方案。法規核准的不斷擴大、醫生認可度的提高、醫院的廣泛應用以及在已開發市場和新興市場的商業化，正推動製藥公司拓展其癌症生物相似藥產品線。 2026年1月，Zydus Lifesciences在印度推出了Tishtha，一種用於治療多種癌症的Nivolumab生物類似藥，其價格約為參考藥物的四分之一，從而提高了免疫腫瘤療法的可及性。

市場定義和範圍

腫瘤生物相似藥市場涵蓋了與已通過核准的用於癌症治療的參考生物製藥高度相似的生物製藥。這些產品為多種癌症適應症提供了治療選擇，同時有助於降低成本並擴大生物製劑的可近性。該市場包括靶向HER2、VEGF、CD20、免疫查核點通路和其他治療標靶的生物相似藥。

該市場按藥物類別、產品、適應症、年齡層、給藥途徑和分銷管道進行細分。主要產品包括曲妥珠單抗、Bevacizumab、Rituximab、Pertuzumab、PembrolizumabNivolumab和Ipilimumab。

市場動態

成長要素

全球癌症負擔日益加重是成長要素的主要因素。這是因為癌症發生率的上升擴大了符合生物製藥治療條件的患者族群。乳癌、肺癌、大腸癌、淋巴瘤和其他惡性腫瘤病例的增加，推動了對曲妥珠單抗、Bevacizumab和Rituximab等療法的需求。已通過核准生物相似藥種類的不斷增加，使醫療系統能夠在控制支出的同時，為更多患者提供生物製藥治療。

價格折扣、醫療採購框架、報銷政策以及醫生對生物相似藥日益深入的了解，也推動了生物相似藥的普及。關鍵查核點抑制劑的專利保護期即將到期，為製藥公司開發新型抗癌生物相似藥創造了更多機會。

趨勢

一個顯著的趨勢是，癌症治療正轉向更具成本效益的生物相似藥。醫院、保險公司和政府採購機構擴大採用生物相似藥物來控制癌症治療預算。製藥公司也紛紛進入查核點抑制劑的生物相似藥市場，包括針對Pembrolizumab和Nivolumab單抗的產品，從而在市場中開闢了新的成長領域。

阻礙因素

價格大幅下跌和利潤率下降是主要阻礙因素。製造商之間的競爭可能會降低平均售價，尤其是對於曲妥珠單抗、Bevacizumab和Rituximab等成熟產品。研發、生產、監管合規和商業化相關的高昂成本可能會進一步擠壓製造商的利潤空間，並為中小企業進入市場設置障礙。

新冠疫情的影響

本報告並未對新冠疫情對腫瘤生物相似藥市場的影響進行具體的量化評估。因此，報告中沒有關於疫情帶來的額外市場價值的說明。本報告目前的市場展望主要基於癌症治療需求、生物相似藥的普及、監管趨勢、定價以及醫藥投資等因素。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 主要地區和國家主要疾病指標的盛行率
  • 主要區域的管道分析
  • 主要地區和國家的監管情況概述
  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）

第5章：2021-2034年全球腫瘤生物相似藥市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 抗HER2單株抗體
    • 抗VEGF單株抗體
    • 抗CD20單株抗體
    • 免疫查核點抑制劑生物相似藥
    • 其他治療性單株抗體
    • 其他
  • 市場分析、洞察與預測：按產品分類。
    • 曲妥珠單抗
    • Bevacizumab
    • Rituximab
    • Pertuzumab
    • Pembrolizumab
    • Nivolumab
    • Ipilimumab
    • 其他
  • 市場分析、洞察與預測：按應用領域分類
    • 乳癌
    • 肺癌
    • 結腸癌
    • 非何傑金氏淋巴瘤
    • 慢性淋巴性白血病
    • 胃癌及胃食道交界處癌
    • 黑色素瘤
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按給藥途徑
    • 靜脈
    • 皮下
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 專科藥房
    • 藥局和零售藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美腫瘤生物相似藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：2021-2034年歐洲腫瘤生物相似藥市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區腫瘤生物相似藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲腫瘤生物相似藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東和非洲腫瘤生物相似藥市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Celltrion, Inc.
    • Amgen Inc.
    • Pfizer Inc.
    • Biocon Biologics Limited
    • Samsung Bioepis Co., Ltd.
    • Sandoz Group AG
    • Shanghai Henlius Biotech, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Organon & Co.
    • Accord Healthcare Limited
    • Fresenius Kabi AG
    • Amneal Pharmaceuticals, Inc.
    • Dr. Reddy's Laboratories Ltd.
Product Code: FBI100578

Growth Factors of oncology biosimilars Market

The global oncology biosimilars market size was valued at USD 9.80 billion in 2025 and is projected to grow from USD 10.74 billion in 2026 to USD 32.25 billion by 2034, exhibiting a CAGR of 14.73% during the forecast period. Asia Pacific dominated the market with a 32.95% share in 2025, valued at USD 3.23 billion, supported by the rising cancer burden, growing demand for affordable biologic treatments, expanding domestic biologics manufacturing, and improving regulatory frameworks. The increasing availability of biosimilars is helping healthcare systems expand access to oncology therapies while managing treatment costs.

Oncology biosimilars are increasingly being adopted as cost-effective alternatives to reference biologic medicines, including monoclonal antibodies and immune-oncology therapies. Growing regulatory approvals, physician acceptance, hospital adoption, and commercialization across developed and emerging markets are encouraging pharmaceutical companies to expand their oncology biosimilar pipelines. In January 2026, Zydus Lifesciences launched Tishtha, a nivolumab biosimilar, in India for multiple cancers at approximately one-fourth of the reference drug's cost, supporting broader access to immune-oncology treatment.

Market Definition and Scope

The oncology biosimilars market includes biologic medicines that are developed to demonstrate high similarity to approved reference biologics used in cancer treatment. These products provide treatment alternatives across several cancer indications while supporting cost containment and broader access to biological therapies. The market encompasses biosimilars targeting HER2, VEGF, CD20, immune checkpoint pathways, and other therapeutic targets.

The market is segmented by drug class, product, application, age group, route of administration, and distribution channel. Major products include trastuzumab, bevacizumab, rituximab, pertuzumab, pembrolizumab, nivolumab, and ipilimumab.

Market Dynamics

Drivers

The rising global cancer burden is a major growth driver because increasing cancer incidence expands the population eligible for biological treatment. Breast cancer, lung cancer, colorectal cancer, lymphoma, and other malignancies are increasing demand for therapies such as trastuzumab, bevacizumab, and rituximab. The expansion of approved biosimilar portfolios is allowing healthcare systems to provide biological treatments to more patients while controlling expenditure.

Price discounts, institutional procurement frameworks, reimbursement policies, and growing physician familiarity are also supporting biosimilar adoption. The upcoming loss of exclusivity for major checkpoint inhibitors is creating additional opportunities for manufacturers to develop new oncology biosimilars.

Trends

A prominent trend is the shift toward cost-effective biosimilar-based cancer treatment. Hospitals, payers, and government procurement organizations are increasingly adopting biosimilars to manage oncology budgets. Manufacturers are also expanding into checkpoint inhibitor biosimilars, including products targeting pembrolizumab and nivolumab, creating a newer growth area within the market.

Restraints

Aggressive price erosion and margin compression represent key restraints. Competition among manufacturers can reduce average selling prices, particularly for established products such as trastuzumab, bevacizumab, and rituximab. High development, manufacturing, regulatory, and commercialization costs can further pressure manufacturer margins and create barriers for smaller companies.

Impact of COVID-19

The provided report does not give a specific quantified COVID-19 impact assessment for the oncology biosimilars market. Therefore, no additional pandemic-related market values are introduced. The current market outlook in the source is primarily based on cancer treatment demand, biosimilar adoption, regulatory developments, pricing, and pharmaceutical investment.

Segmentation Analysis

By drug class, anti-HER2 monoclonal antibodies dominated in 2025, supported by extensive use of trastuzumab and pertuzumab biosimilars in HER2-positive breast and gastric cancers. Immune checkpoint inhibitor biosimilars are projected to grow at a CAGR of 103.89%.

By product, rituximab dominated in 2025 due to its extensive use in hematological cancers and the availability of multiple approved biosimilars. The ipilimumab segment is projected to register a CAGR of 121.37%.

By application, breast cancer held the leading position in 2025 because of its large patient population and extensive use of HER2-targeted biological therapies. The melanoma segment is projected to grow at a CAGR of 104.09%.

By age group, adults dominated the market in 2025, reflecting the larger adult cancer treatment population. By route of administration, intravenous products held the leading position, while the subcutaneous segment is projected to grow at a CAGR of 27.26%. Hospital pharmacies dominated the distribution channel, while online pharmacies are projected to record a CAGR of 21.75%.

Regional Insights

Asia Pacific dominated the market with USD 3.23 billion in 2025 and is estimated to reach USD 3.58 billion in 2026. China, Japan, and India are important regional markets, with 2026 values of approximately USD 1.17 billion, USD 0.77 billion, and USD 0.50 billion, respectively.

North America reached USD 2.48 billion in 2025, supported by biologic cancer therapy utilization, reimbursement coverage, and increasing biosimilar approvals. The U.S. market is estimated at USD 2.55 billion in 2026.

Europe is projected to reach USD 3.50 billion in 2026, supported by physician acceptance, cost-containment policies, and an established biosimilar regulatory framework. The U.K. and Germany are estimated at USD 0.62 billion and USD 0.81 billion, respectively, in 2026.

Competitive Landscape

The oncology biosimilars market includes global and regional pharmaceutical companies competing through regulatory approvals, product launches, clinical development, licensing agreements, acquisitions, and commercialization partnerships. Key companies include Celltrion, Amgen, Pfizer, Biocon Biologics, Samsung Bioepis, Sandoz, Shanghai Henlius Biotech, Teva Pharmaceutical Industries, Organon, Accord Healthcare, Fresenius Kabi, Amneal Pharmaceuticals, and Dr. Reddy's Laboratories.

Report Coverage

The report covers the 2025 market size of USD 9.80 billion, 2026 market value of USD 10.74 billion, and 2034 forecast value of USD 32.25 billion, along with a 14.73% CAGR. It analyzes market drivers, trends, restraints, opportunities, challenges, drug classes, products, applications, age groups, administration routes, distribution channels, regional markets, competitive strategies, regulatory developments, product launches, and industry developments.

Conclusion

The global oncology biosimilars market is projected to expand from USD 9.80 billion in 2025 to USD 10.74 billion in 2026 and USD 32.25 billion by 2034. Rising cancer incidence, increasing demand for affordable biologic therapies, expanding biosimilar approvals, reimbursement support, and growing physician acceptance are supporting market development. The expansion of biosimilars for established oncology medicines and emerging checkpoint inhibitor therapies is expected to remain an important component of the market's development through 2034.

Segmentation By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Region

By Drug Class

  • Anti-HER2 Monoclonal Antibodies
  • Anti-VEGF Monoclonal Antibodies
  • Anti-CD20 Monoclonal Antibodies
  • Immune Checkpoint Inhibitor Biosimilars
  • Other Therapeutic Monoclonal Antibodies
  • Others

By Product

  • Trastuzumab
  • Bevacizumab
  • Rituximab
  • Pertuzumab
  • Pembrolizumab
  • Nivolumab
  • Ipilimumab
  • Others

By Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukemia
  • Gastric & Gastroesophageal Junction Cancer
  • Melanoma
  • Others

By Age Group

  • Pediatric
  • Adults

By Route of Administration

  • Intravenous
  • Subcutaneous
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Disease Indications, By Key Regions, Countries
  • 4.2. Pipeline Analysis, By Key Regions
  • 4.3. Overview of Regulatory Scenario, By Key Regions/Countries
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anti-HER2 Monoclonal Antibodies
    • 5.1.2. Anti-VEGF Monoclonal Antibodies
    • 5.1.3. Anti-CD20 Monoclonal Antibodies
    • 5.1.4. Immune Checkpoint Inhibitor Biosimilars
    • 5.1.5. Other Therapeutic Monoclonal Antibodies
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. Trastuzumab
    • 5.2.2. Bevacizumab
    • 5.2.3. Rituximab
    • 5.2.4. Pertuzumab
    • 5.2.5. Pembrolizumab
    • 5.2.6. Nivolumab
    • 5.2.7. Ipilimumab
    • 5.2.8. Others
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Breast Cancer
    • 5.3.2. Lung Cancer
    • 5.3.3. Colorectal Cancer
    • 5.3.4. Non-Hodgkin's Lymphoma
    • 5.3.5. Chronic Lymphocytic Leukemia
    • 5.3.6. Gastric & Gastroesophageal Junction Cancer
    • 5.3.7. Melanoma
    • 5.3.8. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Pediatric
    • 5.4.2. Adults
  • 5.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.5.1. Intravenous
    • 5.5.2. Subcutaneous
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Specialty Pharmacies
    • 5.6.3. Drug Stores & Retail Pharmacies
    • 5.6.4. Online Pharmacies
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anti-HER2 Monoclonal Antibodies
    • 6.1.2. Anti-VEGF Monoclonal Antibodies
    • 6.1.3. Anti-CD20 Monoclonal Antibodies
    • 6.1.4. Immune Checkpoint Inhibitor Biosimilars
    • 6.1.5. Other Therapeutic Monoclonal Antibodies
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. Trastuzumab
    • 6.2.2. Bevacizumab
    • 6.2.3. Rituximab
    • 6.2.4. Pertuzumab
    • 6.2.5. Pembrolizumab
    • 6.2.6. Nivolumab
    • 6.2.7. Ipilimumab
    • 6.2.8. Others
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Breast Cancer
    • 6.3.2. Lung Cancer
    • 6.3.3. Colorectal Cancer
    • 6.3.4. Non-Hodgkin's Lymphoma
    • 6.3.5. Chronic Lymphocytic Leukemia
    • 6.3.6. Gastric & Gastroesophageal Junction Cancer
    • 6.3.7. Melanoma
    • 6.3.8. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Pediatric
    • 6.4.2. Adults
  • 6.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.5.1. Intravenous
    • 6.5.2. Subcutaneous
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Specialty Pharmacies
    • 6.6.3. Drug Stores & Retail Pharmacies
    • 6.6.4. Online Pharmacies
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anti-HER2 Monoclonal Antibodies
    • 7.1.2. Anti-VEGF Monoclonal Antibodies
    • 7.1.3. Anti-CD20 Monoclonal Antibodies
    • 7.1.4. Immune Checkpoint Inhibitor Biosimilars
    • 7.1.5. Other Therapeutic Monoclonal Antibodies
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. Trastuzumab
    • 7.2.2. Bevacizumab
    • 7.2.3. Rituximab
    • 7.2.4. Pertuzumab
    • 7.2.5. Pembrolizumab
    • 7.2.6. Nivolumab
    • 7.2.7. Ipilimumab
    • 7.2.8. Others
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Breast Cancer
    • 7.3.2. Lung Cancer
    • 7.3.3. Colorectal Cancer
    • 7.3.4. Non-Hodgkin's Lymphoma
    • 7.3.5. Chronic Lymphocytic Leukemia
    • 7.3.6. Gastric & Gastroesophageal Junction Cancer
    • 7.3.7. Melanoma
    • 7.3.8. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Pediatric
    • 7.4.2. Adults
  • 7.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.5.1. Intravenous
    • 7.5.2. Subcutaneous
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Specialty Pharmacies
    • 7.6.3. Drug Stores & Retail Pharmacies
    • 7.6.4. Online Pharmacies
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anti-HER2 Monoclonal Antibodies
    • 8.1.2. Anti-VEGF Monoclonal Antibodies
    • 8.1.3. Anti-CD20 Monoclonal Antibodies
    • 8.1.4. Immune Checkpoint Inhibitor Biosimilars
    • 8.1.5. Other Therapeutic Monoclonal Antibodies
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. Trastuzumab
    • 8.2.2. Bevacizumab
    • 8.2.3. Rituximab
    • 8.2.4. Pertuzumab
    • 8.2.5. Pembrolizumab
    • 8.2.6. Nivolumab
    • 8.2.7. Ipilimumab
    • 8.2.8. Others
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Breast Cancer
    • 8.3.2. Lung Cancer
    • 8.3.3. Colorectal Cancer
    • 8.3.4. Non-Hodgkin's Lymphoma
    • 8.3.5. Chronic Lymphocytic Leukemia
    • 8.3.6. Gastric & Gastroesophageal Junction Cancer
    • 8.3.7. Melanoma
    • 8.3.8. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Pediatric
    • 8.4.2. Adults
  • 8.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.5.1. Intravenous
    • 8.5.2. Subcutaneous
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Specialty Pharmacies
    • 8.6.3. Drug Stores & Retail Pharmacies
    • 8.6.4. Online Pharmacies
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Southeast Asia
    • 8.7.5. Australia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anti-HER2 Monoclonal Antibodies
    • 9.1.2. Anti-VEGF Monoclonal Antibodies
    • 9.1.3. Anti-CD20 Monoclonal Antibodies
    • 9.1.4. Immune Checkpoint Inhibitor Biosimilars
    • 9.1.5. Other Therapeutic Monoclonal Antibodies
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. Trastuzumab
    • 9.2.2. Bevacizumab
    • 9.2.3. Rituximab
    • 9.2.4. Pertuzumab
    • 9.2.5. Pembrolizumab
    • 9.2.6. Nivolumab
    • 9.2.7. Ipilimumab
    • 9.2.8. Others
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Breast Cancer
    • 9.3.2. Lung Cancer
    • 9.3.3. Colorectal Cancer
    • 9.3.4. Non-Hodgkin's Lymphoma
    • 9.3.5. Chronic Lymphocytic Leukemia
    • 9.3.6. Gastric & Gastroesophageal Junction Cancer
    • 9.3.7. Melanoma
    • 9.3.8. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Pediatric
    • 9.4.2. Adults
  • 9.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.5.1. Intravenous
    • 9.5.2. Subcutaneous
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Specialty Pharmacies
    • 9.6.3. Drug Stores & Retail Pharmacies
    • 9.6.4. Online Pharmacies
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Oncology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anti-HER2 Monoclonal Antibodies
    • 10.1.2. Anti-VEGF Monoclonal Antibodies
    • 10.1.3. Anti-CD20 Monoclonal Antibodies
    • 10.1.4. Immune Checkpoint Inhibitor Biosimilars
    • 10.1.5. Other Therapeutic Monoclonal Antibodies
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. Trastuzumab
    • 10.2.2. Bevacizumab
    • 10.2.3. Rituximab
    • 10.2.4. Pertuzumab
    • 10.2.5. Pembrolizumab
    • 10.2.6. Nivolumab
    • 10.2.7. Ipilimumab
    • 10.2.8. Others
  • 10.3. Market Analysis, Insights and Forecast - By Application
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Colorectal Cancer
    • 10.3.4. Non-Hodgkin's Lymphoma
    • 10.3.5. Chronic Lymphocytic Leukemia
    • 10.3.6. Gastric & Gastroesophageal Junction Cancer
    • 10.3.7. Melanoma
    • 10.3.8. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Pediatric
    • 10.4.2. Adults
  • 10.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.5.1. Intravenous
    • 10.5.2. Subcutaneous
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Specialty Pharmacies
    • 10.6.3. Drug Stores & Retail Pharmacies
    • 10.6.4. Online Pharmacies
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Celltrion, Inc.
    • 11.2.2. Amgen Inc.
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Biocon Biologics Limited
    • 11.2.5. Samsung Bioepis Co., Ltd.
    • 11.2.6. Sandoz Group AG
    • 11.2.7. Shanghai Henlius Biotech, Inc.
    • 11.2.8. Teva Pharmaceutical Industries Ltd.
    • 11.2.9. Organon & Co.
    • 11.2.10. Accord Healthcare Limited
    • 11.2.11. Fresenius Kabi AG
    • 11.2.12. Amneal Pharmaceuticals, Inc.
    • 11.2.13. Dr. Reddy's Laboratories Ltd.

List of Tables

  • Table 1: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 3: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021-2034
  • Table 4: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 5: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 6: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 7: Global Oncology Biosimilars Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 9: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021-2034
  • Table 11: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 12: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: North America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 15: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 17: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021-2034
  • Table 18: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 19: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 20: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 21: Europe Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 24: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021-2034
  • Table 25: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 26: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 28: Asia Pacific Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 29: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 30: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 31: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021-2034
  • Table 32: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 33: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 34: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 37: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 38: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Application 2021-2034
  • Table 39: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 40: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 41: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Oncology Biosimilars Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Oncology Biosimilars Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Oncology Biosimilars Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Oncology Biosimilars Market Value Share (%), by Product, 2025 & 2034
  • Figure 4: Global Oncology Biosimilars Market Value Share (%), by Application, 2025 & 2034
  • Figure 5: Global Oncology Biosimilars Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 6: Global Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 8: Global Oncology Biosimilars Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 10: North America Oncology Biosimilars Market Value Share (%), by Drug Class, 2025
  • Figure 11: North America Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034
  • Figure 12: North America Oncology Biosimilars Market Value Share (%), by Product, 2025
  • Figure 13: North America Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034
  • Figure 14: North America Oncology Biosimilars Market Value Share (%), by Application 2025
  • Figure 15: North America Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 16: North America Oncology Biosimilars Market Value Share (%), by Age Group, 2025
  • Figure 17: North America Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 18: North America Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025
  • Figure 19: North America Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Oncology Biosimilars Market Value (USD billion), by Country, 2025 & 2034
  • Figure 22: North America Oncology Biosimilars Market Value Share (%), by Country, 2025
  • Figure 23: Europe Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 24: Europe Oncology Biosimilars Market Value Share (%), by Drug Class, 2025
  • Figure 25: Europe Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034
  • Figure 26: Europe Oncology Biosimilars Market Value Share (%), by Product, 2025
  • Figure 27: Europe Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034
  • Figure 28: Europe Oncology Biosimilars Market Value Share (%), by Application 2025
  • Figure 29: Europe Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 30: Europe Oncology Biosimilars Market Value Share (%), by Age Group, 2025
  • Figure 31: Europe Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Europe Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Europe Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Europe Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Oncology Biosimilars Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Oncology Biosimilars Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Asia Pacific Oncology Biosimilars Market Value Share (%), by Drug Class, 2025
  • Figure 39: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034
  • Figure 40: Asia Pacific Oncology Biosimilars Market Value Share (%), by Product, 2025
  • Figure 41: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034
  • Figure 42: Asia Pacific Oncology Biosimilars Market Value Share (%), by Application 2025
  • Figure 43: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 44: Asia Pacific Oncology Biosimilars Market Value Share (%), by Age Group, 2025
  • Figure 45: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 46: Asia Pacific Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025
  • Figure 47: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 48: Asia Pacific Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025
  • Figure 49: Asia Pacific Oncology Biosimilars Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Oncology Biosimilars Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 52: Latin America Oncology Biosimilars Market Value Share (%), by Drug Class, 2025
  • Figure 53: Latin America Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034
  • Figure 54: Latin America Oncology Biosimilars Market Value Share (%), by Product, 2025
  • Figure 55: Latin America Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034
  • Figure 56: Latin America Oncology Biosimilars Market Value Share (%), by Application 2025
  • Figure 57: Latin America Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 58: Latin America Oncology Biosimilars Market Value Share (%), by Age Group, 2025
  • Figure 59: Latin America Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 60: Latin America Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025
  • Figure 61: Latin America Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 62: Latin America Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025
  • Figure 63: Latin America Oncology Biosimilars Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Oncology Biosimilars Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 66: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Drug Class, 2025
  • Figure 67: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Product, 2025 & 2034
  • Figure 68: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Product, 2025
  • Figure 69: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Application 2025 & 2034
  • Figure 70: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Application 2025
  • Figure 71: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 72: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Age Group, 2025
  • Figure 73: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 74: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Route of Administration, 2025
  • Figure 75: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 76: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Distribution Channel, 2025
  • Figure 77: Middle East & Africa Oncology Biosimilars Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Oncology Biosimilars Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Oncology Biosimilars Market Share (%), by Company, 2025